Literature DB >> 30284684

Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis.

Roman Maslennikov1, Chavdar Pavlov2, Vladimir Ivashkin2.   

Abstract

BACKGROUND: Small intestinal bacterial overgrowth (SIBO) was detected in cirrhosis in many studies. The aim is to perform a systematic review and meta-analysis on the prevalence of SIBO in cirrhosis and on the relationship of SIBO with features of cirrhosis.
METHODS: PUBMED search (until 14 January 2018) was performed. Specific search terms were: '(cirrhosis) AND (SIBO OR bacterial overgrowth)'. Studies not relating to cirrhosis or SIBO, animal studies, and non-original articles were excluded. A meta-analysis of all studies was performed using a random-effects model.
RESULTS: 117 references were identified by the PUBMED search. 3 references were added after handsearching the reference lists of all the articles. 99 references were excluded. 21 studies (included in total 1264 cirrhotics and 306 controls) remained for qualitative analysis and quantitative synthesis. Prevalence of SIBO for cirrhosis was 40.8% (95% CI 34.8-47.1), while the prevalence of SIBO for controls was 10.7% (95% CI 5.7-19.0). OR 6.83 (95% CI 4.16-11.21; p < 0.001). Prevalence of SIBO for decompensated cirrhosis was higher than prevalence of SIBO for compensated cirrhosis (50.5% vs. 31.2%; p < 0.001). SIBO in cirrhosis was associated with ascites (p < 0.001), minimal hepatic encephalopathy (p = 0.001), bacterial translocation (p = 0.026), spontaneous bacterial peritonitis (p = 0.008), prolonged orocecal transit time (p < 0.001), and was not associated with hypocoagulation. Further studies are required to clarify the relationship of SIBO with hyperbilirubinemia, hypoalbuminemia, overt hepatic encephalopathy in past, esophageal varices and systemic inflammation.
CONCLUSION: Small intestinal bacterial overgrowth is more often detected in cirrhosis than in healthy persons and is associated with some features of cirrhosis.

Entities:  

Keywords:  Cirrhosis; Meta-analysis; SIBO; Systematic review

Mesh:

Year:  2018        PMID: 30284684     DOI: 10.1007/s12072-018-9898-2

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  37 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints.

Authors:  Roger M Harbord; Matthias Egger; Jonathan A C Sterne
Journal:  Stat Med       Date:  2006-10-30       Impact factor: 2.373

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

4.  Abnormalities in proximal small bowel motility in patients with cirrhosis.

Authors:  J Chesta; C Defilippi; C Defilippi
Journal:  Hepatology       Date:  1993-05       Impact factor: 17.425

5.  Bacterial translocation in cirrhosis is not caused by an abnormal small bowel gut microbiota.

Authors:  Helen Steed; George T Macfarlane; Katie L Blackett; Sandra Macfarlane; Michael H Miller; Bahram Bahrami; John F Dillon
Journal:  FEMS Immunol Med Microbiol       Date:  2011-09-08

Review 6.  Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.

Authors:  Valerio Giannelli; Vincenza Di Gregorio; Valerio Iebba; Michela Giusto; Serena Schippa; Manuela Merli; Ulrich Thalheimer
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

7.  Frequency and factors associated with small intestinal bacterial overgrowth in patients with cirrhosis of the liver and extra hepatic portal venous obstruction.

Authors:  C P Lakshmi; Uday C Ghoshal; Sunil Kumar; Amit Goel; Asha Misra; Samir Mohindra; G Choudhuri
Journal:  Dig Dis Sci       Date:  2009-05-08       Impact factor: 3.199

8.  Nutrition status and small intestinal bacterial overgrowth in patients with virus-related cirrhosis.

Authors:  Jia Yao; Le Chang; Lili Yuan; Zhongping Duan
Journal:  Asia Pac J Clin Nutr       Date:  2016       Impact factor: 1.662

9.  Small bowel bacterial overgrowth in patients with alcoholic cirrhosis.

Authors:  F C Morencos; G de las Heras Castaño; L Martín Ramos; M J López Arias; F Ledesma; F Pons Romero
Journal:  Dig Dis Sci       Date:  1995-06       Impact factor: 3.199

Review 10.  Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options.

Authors:  Saleh Elwir; Robert S Rahimi
Journal:  J Clin Transl Hepatol       Date:  2017-05-04
View more
  14 in total

1.  Gut dysbiosis and body composition in cirrhosis.

Authors:  Roman Maslennikov; Vladimir Ivashkin; Aliya Alieva; Elena Poluektova; Anna Kudryavtseva; George Krasnov; Maria Zharkova; Yuri Zharikov
Journal:  World J Hepatol       Date:  2022-06-27

2.  Gut Microbiota and Liver Fibrosis: One Potential Biomarker for Predicting Liver Fibrosis.

Authors:  Zhiming Li; Ming Ni; Haiyang Yu; Lili Wang; Xiaoming Zhou; Tao Chen; Guangzhen Liu; Yuanxiang Gao
Journal:  Biomed Res Int       Date:  2020-06-19       Impact factor: 3.411

3.  Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis.

Authors:  Akira Sakamaki; Kunihiko Yokoyama; Fusako Yamazaki; Hiroteru Kamimura; Kenya Kamimura; Masaaki Takamura; Junji Yokoyama; Shuji Terai
Journal:  Intern Med       Date:  2020-04-23       Impact factor: 1.271

Review 4.  Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis.

Authors:  Daniela Campion; Ilaria Giovo; Paola Ponzo; Giorgio M Saracco; Federico Balzola; Carlo Alessandria
Journal:  World J Hepatol       Date:  2019-06-27

Review 5.  Malnutrition in Patients with Liver Cirrhosis.

Authors:  Julia Traub; Lisa Reiss; Benard Aliwa; Vanessa Stadlbauer
Journal:  Nutrients       Date:  2021-02-07       Impact factor: 5.717

Review 6.  Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment.

Authors:  Ramzi Hassouneh; Jasmohan S Bajaj
Journal:  J Clin Med       Date:  2021-01-18       Impact factor: 4.241

7.  Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function.

Authors:  Kunihiko Yokoyama; Akira Sakamaki; Kazuya Takahashi; Takumi Naruse; Chihiro Sato; Yuzo Kawata; Kentaro Tominaga; Hiroyuki Abe; Hiroki Sato; Atsunori Tsuchiya; Kenya Kamimura; Masaaki Takamura; Junji Yokoyama; Shuji Terai
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

Review 8.  The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression.

Authors:  Dishen Chen; Thanh H Le; Haleh Shahidipour; Scott A Read; Golo Ahlenstiel
Journal:  Cells       Date:  2019-10-27       Impact factor: 6.600

Review 9.  Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention.

Authors:  Charlotte Skinner; Alex J Thompson; Mark R Thursz; Julian R Marchesi; Nikhil Vergis
Journal:  Therap Adv Gastroenterol       Date:  2020-10-16       Impact factor: 4.409

10.  Gut dysbiosis is associated with poorer long-term prognosis in cirrhosis.

Authors:  Roman Maslennikov; Vladimir Ivashkin; Irina Efremova; Aliya Alieva; Ekaterina Kashuh; Ekaterina Tsvetaeva; Elena Poluektova; Elena Shirokova; Konstantin Ivashkin
Journal:  World J Hepatol       Date:  2021-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.